Abnova Corporation CEO Dr. Wilber Huang is invited to speak at investor conference held by KGI Securities in Taipei.
Dr. Huang’s speech highlights the inducible T infiltrating lymphocyte (iTIL) cell therapy.

 

Invited Speaker: Wilber Huang, MD
Topic: Inducible T Infiltrating Lymphocyte (iTIL) Cell Therapy
Date: December 12th, 2019
Venue: KGI Securities

 

Abnova

+886-2-87511888

sales@abnova.com

Abnova has established a comprehensive portfolio of fully integrated solutions to address the needs of the in vitro diagnostic (IVD) industry. Abnova provides its partners and customers access to the technologies, products, and services relating to circulating rare cells, circulating exosomes, and circulating cell-free RNA for early to metastatic to recurrent disease and treatment diagnosis, prediction, guidance, and monitoring. Abnova facility is for proprietary bioreagent and high-throughput automation development and manufacturing for clinical trials and IVD commercialization. (www.abnova.com)